Misplaced Pages

Sophia Genetics

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

Sophia Genetics SA
Company typePublic
Traded asNasdaq: SOPH
IndustrySoftware
Cloud computing
Founded2011; 13 years ago (2011)
Founders
  • Dr. Jurgi Camblong
  • Prof. Lars Steinmetz
  • Dr. Pierre Hutter
HeadquartersLausanne, Switzerland
Boston, United States
Key people
  • Dr. Jurgi Camblong (CEO)
  • Ross Muken (CFO)
  • Philippe Menu (CMO)
ServicesSophia DDM Platform
Number of employees400+
Websitesophiagenetics.com

Sophia Genetics SA is a data-driven medicine software company with headquarters in Lausanne, Switzerland and Boston, Massachusetts. It provides genomic and radiomic analysis for hospitals, laboratories, and biopharma institutions.

History

Sophia Genetics was co-founded by Jurgi Camblong, Pierre Hutter, and Lars Steinmetz in 2011 as a start-up at École Polytechnique Fédérale de Lausanne (EPFL). It began as a research tool for hospitals and federally regulated health care labs, and then expanded to biopharma institutions.

In 2014, the company introduced an analytical software platform, the Sophia DDM Platform (Data-Driven Medicine), which helps to interpret circulating tumor DNA and circulating tumour cells in blood, urine, cerebral spinal fluid and other liquid samples. The platform is used for oncology, hereditary cancers, metabolic disorders, pediatrics, cardiology, and for rare disease research.

In 2018, the company set up its first research and development center in France and made acquisition of a France-based molecular biology and genetic analytics software development company, Interactive Biosoftware. That same year, Sophia Genetics opened its U.S. headquarters in Boston, Massachusetts.

In August 2020, the company released a data analysis solution that was focused on predicting the disease evolution of the SARS-CoV-2 virus. Also in 2022, the firm began development of a new method for detecting extrachromosomal DNA through collaboration with startup firm Boundless Bio.

In July 2021, Sophia Genetics went public with an IPO backed by J.P. Morgan, Morgan Stanley, and Credit Suisse.

Partnership

In 2016, Sophia Genetics entered into a comarketing agreement with Illumina allowing the two companies to promote adoption of next- generation DNA sequencing.

In 2019, Sophia Genetics formed partnerships with Integrated DNA Technologies and Paragon Genomics, next-generation sequencing (NGS) assay development company, to provide COVID-19 test kits

In 2021, the company partnered with MGI, a subsidiary of BGI Group, to enable their users to access the SOPHiA DDM Platform for data analysis and interpretation. In March 2021, Sophia Genetics announced a long-term collaboration agreement with Hitachi.

In 2022, the firm committed to a collaboration with Memorial Sloan Kettering Cancer Center to advance predictive tumor analysis and, more broadly, clinical decision support.

References

  1. ^ "Sophia Genetics Partners With MSK on Clinical Decision Support, Boundless Bio on ecDNA Detection". GenomeWeb. 21 September 2022. Retrieved 21 September 2022.
  2. "Sophia Genetics - So Far, So Good..." Nasdaq.
  3. Lomas, Natasha (4 January 2019). "Sophia Genetics bags $77M Series E, with 850+ hospitals signed up to its 'data-driven medicine'". TechCrunch.
  4. Murgia, Madhumita (29 November 2015). "Data-driven medicine: Sophia Genetics becomes largest clinical genomics network". The Daily Telegraph. Retrieved 8 July 2019.
  5. Magistretti, Bérénice (2 January 2017). "Swiss data analytics company Sophia Genetics could be Switzerland's next unicorn". TechCrunch.
  6. Neil, Joshua (16 April 2019). "An Interview with Sophia Genetics: STS and the CE-IVD Designation". Front Line Genomics. Archived from the original on 24 September 2019.
  7. Gaskell, Adi; Wall, Matthew (27 April 2018). "How knowing your genetic code could lengthen your life". BBC News. Retrieved 8 July 2019.
  8. "Genomics testing firm to triple Boston headcount after $110M round". www.bizjournals.com. Retrieved 7 April 2022.
  9. "Sophia genetics". techtour.com. Retrieved 6 May 2022.
  10. Park, Andrea (1 October 2021). "Sophia Genetics teams up with OncoDNA to automate tumor profiling". Fierce Biotech. Retrieved 25 February 2022.
  11. ^ Lomas, Natasha (13 September 2017). "Balderton joins $30M Series D for big data biotech platform play, Sophia Genetics". TechCrunch.
  12. Lerivrain, Hélène (25 April 2018). "La biotech suisse Sophia Genetics continue d'investir et s'installe au Pays basque". La Tribune (in French).
  13. Chavanne, Yannick (18 June 2018). "Sophia Genetics rachète un spécialiste mondial de l'exploration de variations génomiques". ICT Journal (in French).
  14. "Swiss company sets up US headquarters in Boston". BostonGlobe.com. 24 September 2018. Retrieved 17 March 2022.
  15. Taylor, Phil (10 August 2020). "Sophia Genetics launches AI tool to find COVID-19 'unknowns' -". pharmaphorum.com. Retrieved 24 March 2022.
  16. Walrath, Rowan (26 July 2021). "Sophia Genetics goes public in $234M IPO, two other biotechs delay". Boston Business Journal. Retrieved 11 December 2024.
  17. Versel, Neil (23 July 2021). "Sophia Genetics Raises $234M in IPO, Eyes Additional Partnerships". GenomeWeb. Retrieved 11 December 2024.
  18. "Illumina, Sophia Genetics to Comarket NGS Solutions for Clinical Dx". GenomeWeb.
  19. "IDT, Sophia Genetics Broaden Partnership to Clinical-Grade Technologies". Clinical OMICs - Molecular Diagnostics in Precision Medicine. 17 January 2020.
  20. "Sophia Genetics, Paragon Genomics Team on SARS-CoV-2 Testing". Clinical OMICs - Molecular Diagnostics in Precision Medicine. 26 March 2020.
  21. "Sophia Genetics to Provide Access to Genomic Analysis Platform to MGI Customers". GenomeWeb.
  22. "Hitachi enters collaboration for data driven precision medicine". www.biospectrumasia.com. Retrieved 28 April 2022.

External links

Categories: